SCHEMBL4665207

SCHEMBL4665207

N#Cc1ccc(NC(=O)NC(=N)Nc2ccc(Cl)cc2)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.74
LMNA P02545 2/20 0.74
TSHR P16473 1/20 0.74
HTT P42858 1/20 0.74
NLRP3 Q96P20 1/20 0.74
CNR1 P21554 2/20 0.58
ALDH1A1 P00352 3/20 0.52
KDM4E B2RXH2 2/20 0.52
GLA P06280 1/20 0.52
GAA P10253 1/20 0.52
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
POLB P06746 2/20 0.51
SAE1 Q9UBE0 1/20 0.51
UBA2 Q9UBT2 1/20 0.51
PKM P14618 1/20 0.51
MAPK1 P28482 1/20 0.51
RAB9A P51151 1/20 0.51
IL18 Q14116 1/20 0.51
EPHX2 P34913 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4116856 0.86 MAPT (1.00) MAPTLMNATSHRHTTNLRP3
SCHEMBL10668018 0.77 IDO1 (0.55) MAPTLMNATSHRHTTNLRP3
SCHEMBL11054945 0.77 MAPT (0.81) MAPTLMNATSHRHTTNLRP3
SCHEMBL20941635 0.76 MAPT (0.75) MAPTLMNATSHRHTTNLRP3
SCHEMBL11236184 0.75 NPC1 (0.50) MAPTLMNATSHRHTTNLRP3
SCHEMBL21645391 0.74 IDO1 (0.50) MAPTLMNATSHRHTTNLRP3
SCHEMBL16872738 0.74 CNR1 (0.49) CNR1ALDH1A1RAB9A
SCHEMBL4349313 0.74 MAPT (0.70) MAPTLMNATSHRHTTNLRP3
SCHEMBL13097207 0.74 MAPT (0.51) MAPTLMNATSHRHTTNLRP3
SCHEMBL22834250 0.73 CNR1 (1.00) MAPTLMNATSHRHTTNLRP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1888626-A2 A THERAPEUTIC AGENT FOR AB RELATED DISORDERS Eisai R&D Management Co., Ltd. (JP) 2008-02-20 EP disclosed
US-20060241038-A1 Therapeutic agent for Abeta related disorders EISAI CO., LTD. (JP) 2006-10-26 US disclosed
WO-2006112550-A2 A THERAPEUTIC AGENT FOR Aβ RELATED DISORDERS EISAI R & D MANAGEMENT CO., LTD. (JP) 2006-10-26 WO disclosed
WO-2006112551-A2 A THERAPEUTIC AGENT FOR Aβ RELATED DISORDERS EISAI CO., LTD. (JP) 2006-10-26 WO disclosed
WO-2006112552-A2 THERAPEUTIC AGENTS FOR ABETA RELATED DISORDERS EISAI CO., LTD. (JP) 2006-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241038-A1 Therapeutic agent for Abeta related disorders APP, BACE1, PSEN1 MAPT 9/4885LMNA 2088/4885TSHR 4455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.